2-deoxy-d-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial

BACKGROUND: At present, no single efficacious therapeutic exists for acute COVID-19 management and a multimodal approach may be necessary. 2-deoxy-d-glucose (2-DG) is a metabolic inhibitor that has been shown to limit multiplication of SARS-CoV-2 in-vitro. We evaluated the efficacy and safety of 2-D...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatt, Anant Narayan, Shenoy, Srinivas, Munjal, Sagar, Chinnadurai, Vijayakumar, Agarwal, Apurva, Vinoth Kumar, A., Shanavas, A., Kanwar, Ratnesh, Chandna, Sudhir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351257/
https://www.ncbi.nlm.nih.gov/pubmed/35927676
http://dx.doi.org/10.1186/s12879-022-07642-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351257/
https://www.ncbi.nlm.nih.gov/pubmed/35927676
http://dx.doi.org/10.1186/s12879-022-07642-6

Ejemplares similares